| 234.715 2.575 (1.11%) | 01-23 15:44 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 277.08  |
1-year : | 323.63 |
| Resists | First : | 237.22 |
Second : | 277.08 |
| Pivot price | 217.8  |
|||
| Supports | First : | 216.77 |
Second : | 204.13 |
| MAs | MA(5) : | 227.58 |
MA(20) : | 216.08 |
| MA(100) : | 226.39 |
MA(250) : | 254.44 |
|
| MACD | MACD : | 1.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 89.2 |
D(3) : | 85.5 |
| RSI | RSI(14): 64.7 |
|||
| 52-week | High : | 335.39 | Low : | 196.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALGN ] has closed Bollinger Bands are 10.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 237.37 - 238.07 | 238.07 - 238.86 |
| Low: | 223.48 - 224.31 | 224.31 - 225.25 |
| Close: | 230.64 - 231.92 | 231.92 - 233.36 |
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Thu, 23 Jan 2025
The Analyst Verdict: Align Tech In The Eyes Of 3 Experts - Benzinga
Thu, 23 Jan 2025
Riverbridge Partners LLC Sells 25,320 Shares of Align Technology, Inc. (NASDAQ:ALGN) - MarketBeat
Wed, 22 Jan 2025
Align Technology (ALGN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Tue, 21 Jan 2025
Align Technology Earnings Preview: What to Expect - MSN
Tue, 21 Jan 2025
Why Align Technology (ALGN) Could Beat Earnings Estimates Again - Yahoo Finance
Thu, 16 Jan 2025
Align Technology Shares Hurt by Macro Issues, Decline in ASPs - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 75 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 89.8 (%) |
| Shares Short | 2,660 (K) |
| Shares Short P.Month | 3,000 (K) |
| EPS | 5.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 52.75 |
| Profit Margin | 11.1 % |
| Operating Margin | 16.6 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 11.3 % |
| Qtrly Rev. Growth | 1.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 53.04 |
| EBITDA (p.s.) | 10.98 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 499 (M) |
| Levered Free Cash Flow | 413 (M) |
| PE Ratio | 40.11 |
| PEG Ratio | 0 |
| Price to Book value | 4.44 |
| Price to Sales | 4.42 |
| Price to Cash Flow | 35.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|